1911578-98-7Relevant articles and documents
Dynamic kinetic resolution method for tail chain of Remdesivir phosphoric acid intermediate
-
Paragraph 0049-0052, (2021/09/21)
The invention relates to a drug intermediate of an RNA polymerase inhibitor, in particular to an intermediate of Remdesivir phosphate and a preparation method of the intermediate. According to the method, a compound Sp/Rp epimerization mixture in a formula (I) is crystallized under a dynamic kinetic resolution condition, so that the Rp single configuration isomer, in a formula (I'), of the Remdesivir intermediate is obtained. In the synthesis process, an epimerization mixture of the compound shown in the formula (I) is finally converted into a single-configuration I'compound through crystallization-induced epimerization under the dynamic kinetic resolution condition, so that the total yield of the reaction is increased, the utilization rate of raw materials is increased, and the process is more environmentally friendly and efficient.
2,4,7-SUBSTITUTED-7-DEAZA-2'-DEOXY-2'-FLUOROARABINOSYL NUCLEOSIDE AND NUCLEOTIDE PRO-DRUGS AND USES THEREOF
-
, (2020/12/30)
The present disclosure is concerned with 2,4,7-substituted-7-deaza-2'-deoxy-2'- fluoroarabinosyl nucleoside and nucleotide prodrugs that are capable of inhibiting viral infections and methods of treating viral infections such as, for example, human immunodeficiency virus (HIV), human papillomavirus (HPV), herpes simplex virus (HSV), human cytomegalovirus (HCMV), chicken pox, infectious mononucleosis, mumps, measles, rubella, shingles, ebola, viral gastroenteritis, viral hepatitis, viral meningitis, human metapneumovirus, human parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, respiratory syncytial virus, viral pneumonia, Chikungunya virus (CHIKV), Venezuelan equine encephalitis (VEEV), dengue (DENV), influenza, West Nile virus (WNV), zika (ZIKV), 229E, NL63, OC43, HKU1, Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV), and severe acute respiratory syndrome coronavirus disease 2019 (SARS-CoV-2), using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
THIARABINE- AND THIARABINE PRODRUG-BASED TREATMENTS
-
, (2020/12/29)
The present disclosure is concerned with combination therapies that include sulfur- based nucleotide and nucleoside compounds for the treatment of various cancers such as, for example, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, bladder cancer, thyroid cancer, testicular cancer, pancreatic cancer, endometrial cancer, melanomas, gliomas, leukemias, lymphomas, chronic myeloproliferative disorders, myelodysplastic syndromes, myeloproliferative neoplasms, and plasma cell neoplasms (myelomas). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.